Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)

NCT03891576 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

83

Enrollment

OTHER

Sponsor class

Stopped Low accrual rate

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Carcinoma

Interventions

DRUG: Niraparib

Sponsor

Mario Negri Institute for Pharmacological Research

Collaborators

[object Object]